Hereditary tyrosinemia type I: A new clinical classification with difference in prognosis on dietary treatment
Corresponding Author
Francjan J. Van Spronsen M.D.
Beatrix Children's Hospital, University of Groningen, 9713 EZ Groningen, The Netherlands
Beatrix Children's Hospital, University Hospital of Groningen, 59 Oostersingel, 9713 EZ Groningen, The Netherlands===Search for more papers by this authorYolande Thomasse
Beatrix Children's Hospital, University of Groningen, 9713 EZ Groningen, The Netherlands
Search for more papers by this authorG. Peter A. Smit
Beatrix Children's Hospital, University of Groningen, 9713 EZ Groningen, The Netherlands
Search for more papers by this authorJames V. Leonard
Department of Medical Statistics, University of Groningen, 9713 EZ Groningen, The Netherlands
Search for more papers by this authorPeter T. Clayton
Department of Medical Statistics, University of Groningen, 9713 EZ Groningen, The Netherlands
Search for more papers by this authorVaclav Fidler
The Institute of Child Health, London, United Kingdom
Search for more papers by this authorRuud Berger
Beatrix Children's Hospital, University of Groningen, 9713 EZ Groningen, The Netherlands
Search for more papers by this authorHugo S. A. Heymans
Beatrix Children's Hospital, University of Groningen, 9713 EZ Groningen, The Netherlands
Search for more papers by this authorCorresponding Author
Francjan J. Van Spronsen M.D.
Beatrix Children's Hospital, University of Groningen, 9713 EZ Groningen, The Netherlands
Beatrix Children's Hospital, University Hospital of Groningen, 59 Oostersingel, 9713 EZ Groningen, The Netherlands===Search for more papers by this authorYolande Thomasse
Beatrix Children's Hospital, University of Groningen, 9713 EZ Groningen, The Netherlands
Search for more papers by this authorG. Peter A. Smit
Beatrix Children's Hospital, University of Groningen, 9713 EZ Groningen, The Netherlands
Search for more papers by this authorJames V. Leonard
Department of Medical Statistics, University of Groningen, 9713 EZ Groningen, The Netherlands
Search for more papers by this authorPeter T. Clayton
Department of Medical Statistics, University of Groningen, 9713 EZ Groningen, The Netherlands
Search for more papers by this authorVaclav Fidler
The Institute of Child Health, London, United Kingdom
Search for more papers by this authorRuud Berger
Beatrix Children's Hospital, University of Groningen, 9713 EZ Groningen, The Netherlands
Search for more papers by this authorHugo S. A. Heymans
Beatrix Children's Hospital, University of Groningen, 9713 EZ Groningen, The Netherlands
Search for more papers by this authorAbstract
Hereditary tyrosinemia type I (McKusick 27670) is a heterogeneous disease with poor prognosis, yet there are few reports of the long-term prognosis. It is therefore difficult to decide on the treatment for individual patients. We have conducted an international survey of patients with tyrosinemia type I and examined the probability of survival on dietary treatment and the causes of death in 108 patients with tyrosinemia type I. The survival after the onset of symptoms varied with the age at onset; the earlier the symptoms developed the poorer the outlook. Liver failure and recurrent bleeding (67%), hepatocellular carcinoma (17%) and the porphyria-like syndrome with respiratory failure (10%) were the most common causes of death. The 1-and 2-yr survival probability after the onset of symptoms in patients in whom symptoms developed before 2 mo, between 2 and 6 mo and after 6 mo were 38%/29%, 74%/74% and 96%/96%, respectively. On the basis of these survival rates, a new classification - which is important with respect to choices in treatment — is proposed: very early (onset of symptoms < 2 mo), early (2 to 6 mo) and late presenting form (>6 mo). (Hepatology 1994;20:1187–1191).
References
- 1 Lindblad B, Lindstedt S, Steen G. On the enzymatic defects in hereditary tyrosinemia. Proc Natl Acad Sci U S A 1977; 74: 4641–4645.
- 2 Berger R, Smit GPA, Stoker-de Vries SA, Duran M, Ketting D, Wadman SK. Deficiency of fumarylacetoacetase in a patient with hereditary tyrosinemia. Clin Chim Acta 1981; 114: 37–44.
- 3
Halvorsen S.
Tyrosinemia.
In: J Fernandes,
J-M Saudubray,
K Tada, eds.
Inborn metabolic diseases: diagnosis and treatment.
Berlin:
Springer Verlag,
1990:
199–209.
10.1007/978-3-662-02613-7_16 Google Scholar
- 4 Goldsmith LA, Laberge C. Tyrosinemia and related disorders. In: CR Scriver, AL Beaudet, WS Sly, D Valle, eds. The metabolic basis of inherited disease. New York: McGraw Hill Inc., 1989: 547–562.
- 5 Kvittingen EA. Hereditary tyrosinemia type I an overview. Scand J Clin Lab Invest 1986; 46: S184;27–34.
- 6 Lindstedt S, Holme E, Lock EA, Hjalmarson O, Strandvik B. Treatment of hereditary tyrosinemia type I by inhibition of 4-hydroxyphenyl-pyruvate dioxygenase. Lancet 1992; 340: 813–817.
- 7 Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. New York: Wiley, 1980.
- 8 Larochelle J, Privé L, Bélanger M, Bélanger L, Tremblay M, Claveau J-C, Aubin G, et al. Tyrosinémie héréditaire. I. Etude clinique et biologique de 62 cas. Pédiatrie 1973;T 28: 5–18.
- 9 Mowat AP. Liver disorders in children: the indications for liver replacement in parenchymal and metabolic diseases. Transplant Proc 1987; 19: 3236–3241.
- 10 Tanguay RM, Laberge C, Lescault A, Valet JP, Duband JL, Quenneville Y. Molecular basis of hereditary tyrosinemias: Proof of the primary defect by Western blotting. In: WA Scott, F Ahmad, S Black, J Schultz, WJ Whelan, eds. Advances in gene technology: human genetic disorders. Cambridge, UK: Cambridge University Press, 1984: 250–251.
- 11 Berger R, van Faassen H, Taanman JW, de Vries H, Agsteribbe A. Type I tyrosinemia: lack of immunologically detectable fumarylacetoacetase enzyme protein in tissues and cell extracts. Pediatr Res 1987; 22: 394–398.
- 12 Berger R, van Faassen H, Taanman JW, de Vries H, Agsteribbe A. Different types of mutations in the chronic and acute forms of type I tyrosinemia [Abstract]. Pediatr Res 1988; 24: 266.
- 13 Kvittingen EA, Rootwelt H, van Dam T, van Faassen H, Berger R. Hereditary tyrosinemia type I — lack of correlation between clinical findings and amount of immunoreactive fumaryl-acetoacetase protein. Pediatr Res 1992; 31: 43–46.
- 14 Phaneuf D, Lambert M, Laframboise R, Mitchell G, Lettre F, Tanguay RM. Type I hereditary tyrosinemia. Evidence for molecular heterogeneity and identification of a causal mutation in a French Canadian patient. J Clin Invest 1992; 90: 1185–1192.
- 15 Rootwelt H, Berger R, Ozalp I, Brodtkorb E, Höie K, Kvittingen EA., Mutational diversity in hereditary tyrosinaemia type 1 [Abstract]. Thirty-first annual symposium of the Society for the Study of Inborn Errors of Metabolism, Manchester, UK, September 1993.
- 16 Ploos van Amstel JK, Peelen T, Leeftink M, Van den Berg, I, Kvittingen EA, Berger R. Heterogeneity and mosaicism of fumarylacetoacetase (FAH) mRNA and protein in hereditary tyrosinemia type I [Abstract]. Thirty-first annual symposium of the Society for the Study of Inborn Errors of Metabolism, Manchester, UK, September 1993.
- 17 Weinberg AG, Mize CE, Worthen HG. The occurrence of hepatoma in the chronic form of hereditary tyrosinemia. J Pediatr 1976; 88: 434–438.
- 18 Mitchell G, Larochelle J, Lambert M, Michaud J, Grenier A, Ogier H, Gautier M, et al. Neurologic crises in hereditary tyrosinemia. N Engl J Med 1990; 15: 432–437.
- 19 Kvittingen EA, Talseth T, Halvorsen S, Jakobs C, Hovig T, Flatmark A. Renal failure in adult patients with hereditary tyrosinaemia type I. J Inherit Metab Dis 1991; 14: 53–62.
- 20
Edwards MA,
Green A,
Colli A,
Rylance G.
Tyrosinemia type I and hypertrophic obstructive cardiomyopathy.
Lancet
1987;
I: 1437.
10.1016/S0140-6736(87)90631-3 Google Scholar
- 21 Starzl TE, Esquivel C, Gordon R, Todo S. Pediatric liver transplantation. Transplant Proc 1987; 19: 3230–3235.
- 22 van Spronsen FJ, Smit GPA, Slooff MJH, Bijleveld CMA, Klompmaker IJ, Koetse HA, Heymans HSA. Indication and timing of liver replacement in inherited metabolic disorders. Intensive Crit Care Dig 1992; 11: 23–26.
- 23 Van Spronsen FJ, Berger R, Smit GPA, de Klerk JBC, Duran M, Biljeveld CMA, van Faassen H, et al. Tyrosinaemia type I: orthotopic liver transplantation as the only definitive answer to a metabolic as well as an oncological problem. J Inherit Metab Dis 1989;12;S 2: 339–342.
- 24 Salt A, Barnes ND, Rolles K, Calne RY, Clayton PT, Leonard JV. Liver transplantation in tyrosinemia type I. Acta Paediatr 1992; 81: 449–452.
- 25 Esquivel CO, Mieles L, Marino IR, Todo S, Makowka L, Ambrosin G, Nakazato P, et al. Liver transplantation for hereditary tyrosinemia in the presence of hepatocellular carcinoma. Transplant Proc 1989; 21: 2445–2446.
- 26 Mieles LA, Esquivel CO, van Thiel DH, Koneru B, Makowka L, Tzakis AG, Starzl TE. Liver transplantation for tyrosinemia. A review of 10 cases from the University of Pittsburgh. Dig Dis Sci 1990; 35: 153–157.
- 27 Freese DK, Tuchman M, Schwarzenberg SJ, Sharp HL, Rank JM, Bloomer JR, Ascher NL, et al. Early liver transplantation is indicated for tyrosinemia type I. J Pediatr Gastroenterol Nutr 1991; 13: 10–15.
- 28 Paradis K, Weber A, Seidman EG, Larochelle J, Garel L, Lenaerts C, Roy CC. Liver transplantation for hereditary tyrosinemia: the Quebec experience. Am J Hum Genet 1990; 47: 338–342.
- 29 Sokal EM, Bustos R, van Hoof F, Otte JB. Liver transplantation for hereditary tyrosinemia: early transplantation following the patient's stabilization. Transplantation 1992; 54: 937–9.
- 30 Holme E, Lindstedt S. Neonatal screen for hereditary tyrosinemia type I. Lancet 1992; 340: 850.
- 31 Laberge C, Grenier A, Valet JP, Morissette J. Fumarylacetoacetase measurement as a mass-screening procedure for hereditary tyrosinemia type I. Am J Hum Genet 1990; 47: 325–328.